Glytec Rapidly Analyzes Data to Publish Critical Medical Research During COVID-19 Glytec believes that every patient is unique, and their insulin management should be too. Thirty-four million people in the U.S. are living with diabetes, and 30%-40% of hospitalized inpatients (with or without diabetes) require insulin therapy during their hospital stay. With access to Glytec’s patented and FDA-cleared software and data reporting, healthcare providers have the analytics insights they need to improve patient outcomes, decrease length of stay and readmissions, cut instances of hypo and hyperglycemic events during hospital stays, and — contrary to popular assumptions in the healthcare space — significantly reduce the costs associated with insulin management. Robby Booth, founder and SV

Join for free to read